2
Clinical Trials associated with Bone marrow derived mesenchymal stem cell therapy (Taiwan Bio Therapeutics) / Active, not recruitingPhase 2 A Phase IIb Study to Evaluate the Efficacy and Safety of Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA)
This is a randomized, single-blind, parallel, active-controlled study to evaluate the efficacy and safety of bone marrow mesenchymal stem cells (BM-MSCs), Chondrochymal®, in subjects aged 40 to 80 with knee OA.
A Phase I/IIa Clinical Study of Treatment for Knee Osteoarthritis by Intra-articular Injection of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells.
The Clinical trial is a phase I/IIa clinical study for treatment of knee osteoarthritis by intra-articular injection of bone marrow derived allogeneic mesenchymal stem cells. Primary endpoint of the study is safety of allogeneic BM-MSCs application on knee OA with single dose IA injection and the MTD. Secondary endpoint is the effect of allogeneic BM-MSCs transplantation including clinical and image observation since the MSCs have multi-lineage differentiation potential such as chondrocyte differentiation, anti-inflammation and immune-modulation.
100 Clinical Results associated with Bone marrow derived mesenchymal stem cell therapy (Taiwan Bio Therapeutics)
100 Translational Medicine associated with Bone marrow derived mesenchymal stem cell therapy (Taiwan Bio Therapeutics)
100 Patents (Medical) associated with Bone marrow derived mesenchymal stem cell therapy (Taiwan Bio Therapeutics)
100 Deals associated with Bone marrow derived mesenchymal stem cell therapy (Taiwan Bio Therapeutics)